Literature DB >> 35094342

Using Optical Tweezers to Dissect Allosteric Communication Networks in Protein Kinases.

Yuxin Hao1, Rodrigo Maillard2.   

Abstract

Mutations in protein kinases are often associated with the development of cancer, and application of mutant-specific inhibitors as therapeutic measures have shown a remarkable improvement in prolonging patient survival. However, it has also been observed that tumors bearing certain mutation types are more resistant to current approved drugs. Importantly, many resistant mutations are located in regions outside substrate or inhibitor binding sites, indicating allosteric effects. Understanding how mutations trigger effects over a distant site of the protein requires a deeper investigation of the molecular origin of allosteric regulation networks in kinases. In this chapter, we show the application of single-molecule optical tweezers to selectively manipulate specific regions of proteins to trace allosteric signals, thereby allowing the elucidation of allosteric communication networks. We illustrate this approach using as model system the regulatory subunit of protein kinase A. This single-molecule optical tweezers approach, however, can be readily applicable to study other kinases, and can be further expanded to screen potential allosteric drugs for future therapeutics.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Allostery; DNA-protein covalent attachment; Force-extension curves; Kinases; Mechanical fingerprints; Selective manipulation; Single molecule optical tweezers

Mesh:

Substances:

Year:  2022        PMID: 35094342      PMCID: PMC8884448          DOI: 10.1007/978-1-0716-1811-0_25

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  30 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Mutations and polymorphisms in the gene encoding regulatory subunit type 1-alpha of protein kinase A (PRKAR1A): an update.

Authors:  Anélia Horvath; Jérôme Bertherat; Lionel Groussin; Marine Guillaud-Bataille; Kitman Tsang; Laure Cazabat; Rosella Libé; Elaine Remmers; Fernande René-Corail; Fabio Rueda Faucz; Eric Clauser; Alain Calender; Xavier Bertagna; J Aidan Carney; Constantine A Stratakis
Journal:  Hum Mutat       Date:  2010-04       Impact factor: 4.878

3.  Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches.

Authors:  Scott A Foster; Christiaan Klijn; Shiva Malek
Journal:  Trends Cancer       Date:  2016-11-21

4.  Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

Authors:  Jianjiong Gao; Bülent Arman Aksoy; Ugur Dogrusoz; Gideon Dresdner; Benjamin Gross; S Onur Sumer; Yichao Sun; Anders Jacobsen; Rileen Sinha; Erik Larsson; Ethan Cerami; Chris Sander; Nikolaus Schultz
Journal:  Sci Signal       Date:  2013-04-02       Impact factor: 8.192

5.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.

Authors:  Axel Hauschild; Jean-Jacques Grob; Lev V Demidov; Thomas Jouary; Ralf Gutzmer; Michael Millward; Piotr Rutkowski; Christian U Blank; Wilson H Miller; Eckhart Kaempgen; Salvador Martín-Algarra; Boguslawa Karaszewska; Cornelia Mauch; Vanna Chiarion-Sileni; Anne-Marie Martin; Suzanne Swann; Patricia Haney; Beloo Mirakhur; Mary E Guckert; Vicki Goodman; Paul B Chapman
Journal:  Lancet       Date:  2012-06-25       Impact factor: 79.321

6.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors:  Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 7.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

8.  Structure of a PKA RIα Recurrent Acrodysostosis Mutant Explains Defective cAMP-Dependent Activation.

Authors:  Jessica Gh Bruystens; Jian Wu; Audrey Fortezzo; Jason Del Rio; Cole Nielsen; Donald K Blumenthal; Ruth Rock; Eduard Stefan; Susan S Taylor
Journal:  J Mol Biol       Date:  2016-11-05       Impact factor: 5.469

Review 9.  New perspectives for targeting RAF kinase in human cancer.

Authors:  Zoi Karoulia; Evripidis Gavathiotis; Poulikos I Poulikakos
Journal:  Nat Rev Cancer       Date:  2017-10-06       Impact factor: 60.716

10.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.